Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.
about
Oxidative stress responses and NRF2 in human leukaemiaMetabolic control of cancer cell stemness: Lessons from iPS cellsRational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem CellsCovalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition ReactionsPiperlongumine inhibits migration of glioblastoma cells via activation of ROS-dependent p38 and JNK signaling pathways.Selenium suppresses leukemia through the action of endogenous eicosanoids.Heterocyclic aminoparthenolide derivatives modulate G(2)-M cell cycle progression during Xenopus oocyte maturation.Reactive oxygen species in normal and tumor stem cells.Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment.Nanodelivery of Parthenolide Using Functionalized Nanographene Enhances its Anticancer Activity.Stem cells and the impact of ROS signaling.Anti-cancer activity of carbamate derivatives of melampomagnolide B.A ROS-Activatable Agent Elicits Homologous Recombination DNA Repair and Synergizes with Pathway CompoundsOrgan-specific adaptive signaling pathway activation in metastatic breast cancer cellsMicheliolide overcomes KLF4-mediated cisplatin resistance in breast cancer cells by downregulating glutathioneNormal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid LeukemiaHydroxylated Dimeric Naphthoquinones Increase the Generation of Reactive Oxygen Species, Induce Apoptosis of Acute Myeloid Leukemia Cells and Are Not Substrates of the Multidrug Resistance Proteins ABCB1 and ABCG2Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor CellsATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia.Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.Aldehyde dehydrogenases in acute myeloid leukemia.Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?Anticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis.Synthesis and antileukemic activities of C1-C10-modified parthenolide analogues.A small molecule that induces reactive oxygen species via cellular glutathione depletion.Structural and Biochemical Analyses Reveal the Mechanism of Glutathione S-Transferase Pi 1 Inhibition by the Anti-cancer Compound Piperlongumine.Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine.Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs.Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1.Piperlongumine reverses doxorubicin resistance through the PI3K/Akt signaling pathway in K562/A02 human leukemia cells.The purified vepoloxamer prevents haemolysis in 42-day stored, DEHP/PVC-free red blood cell units.NRF2-regulated metabolic gene signature as a prognostic biomarker in non-small cell lung cancer.Pharmacological targeting of glucose-6-phosphate dehydrogenase in human erythrocytes by Bay 11-7082, parthenolide and dimethyl fumarate.PKC epsilon is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.N-[11CH3]Dimethylaminoparthenolide (DMAPT) uptake into orthotopic 9LSF glioblastoma tumors in the rat.15-Methylene-Eburnamonine Kills Leukemic Stem Cells and Reduces Engraftment in a Humanized Bone Marrow Xenograft Mouse Model of Leukemia.Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells.Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia.Succinamide derivatives of melampomagnolide B and their anti-cancer activities.
P2860
Q26864239-F2EAF9FD-C6E4-42DB-81D5-B838C12EE1A4Q28081608-A881A164-20B1-4134-8C62-C510EFD67058Q28391575-B159C4F0-8A50-45E8-A6BB-F8B398911220Q29248430-06349F53-D7ED-4612-9CE5-DBC6DA8CC694Q33748476-D837AA25-1C25-4029-87D8-2D035B300EABQ33916841-291EB94A-F53B-4133-8AC0-161BF17E0556Q34003080-054DEDE3-C362-45BC-8E79-C3449FEAC2E2Q34392752-A8F2C52E-FD1F-4A5B-AEDF-F0D0FBCCD50CQ34676418-3BE0EA6D-6171-471F-82FD-2E27FBAC26ECQ34822470-54DA5EAF-1081-4F4E-9D7D-5969E828DDA1Q34999296-ADB23EA5-A28F-4A51-A001-EA0588793FCFQ35239721-C1A35C24-91E8-4CC3-AF34-228200D6774BQ35792527-1F888BA9-398A-4F73-9C73-DE6F08E02D82Q35828652-9AE6CCBB-30EA-4BCF-9002-DF347BFC00F0Q36024718-517354ED-A1D5-4B38-88A1-EDEC9B7218FBQ36144842-73AD1430-1F4E-4AAC-B712-B5BC1A1E960BQ36741711-21309635-8F19-409C-9A49-D2A360402676Q37122892-328AA13A-8B5A-49BD-9C70-1DB163932F5FQ37379680-93F712BE-A2F8-40B2-AB35-7B21F10010A2Q37452241-B7210AB7-975E-4F74-B248-ACD4B3E6C10BQ38196948-17F56D35-E2B5-4C95-B2E0-69AA66F926FCQ38606849-73AD94EA-9505-481C-A3F8-F753601D036AQ38639453-8F3A7EFF-28BA-4AB3-A900-8B41A4B04E3BQ38862410-B8936945-FC0D-438C-94CF-EF95AC395287Q38976630-B202AA9E-4DED-487E-A699-4090D59B5030Q39166555-0A3366A9-7FB0-4746-B50E-48A7C298EC30Q39249420-DAEFE407-1489-43A4-92E9-FFBC029A19A1Q41601675-331A8789-B59C-4745-AD72-521BF19DCB96Q41937047-0CE85704-9F2D-4AF9-A259-7960C62E7658Q42167869-A550ACCC-FA39-4E0E-B9E4-1CF59A799798Q42318588-C144A8EE-25C8-4F95-B660-B97131F51873Q42378386-3857CDCE-5B27-46EF-BE9B-F555B9577029Q42519382-4D760727-53DA-4B69-890D-1ECA47F9B459Q46263645-C6478CA7-6A41-4577-8901-2DF3066D32E1Q46300745-65C3442F-792A-47AE-A18B-C83151F63DBAQ47144695-0C49EE96-F29D-476C-8D55-6F3F3D1F0D15Q47604411-6932583F-C69C-4BEF-906A-8DB5F144C375Q48034568-CCD46278-3BAB-4A5C-AC77-F88F6F7AAC5BQ49702436-AA84C372-CD16-4B96-8FEB-6099A6021D25Q50978979-D5A1A376-6862-4597-BDDE-D8D8456F9D42
P2860
Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells.
description
2013 թվականի հոկտեմբերի 2-ին հրատարակված գիտական հոդված
@hy
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
name
Targeting aberrant glutathione ...... te myelogenous leukemia cells.
@en
Targeting aberrant glutathione ...... te myelogenous leukemia cells.
@nl
type
label
Targeting aberrant glutathione ...... te myelogenous leukemia cells.
@en
Targeting aberrant glutathione ...... te myelogenous leukemia cells.
@nl
prefLabel
Targeting aberrant glutathione ...... te myelogenous leukemia cells.
@en
Targeting aberrant glutathione ...... te myelogenous leukemia cells.
@nl
P2093
P2860
P50
P356
P1476
Targeting aberrant glutathione ...... ute myelogenous leukemia cells
@en
P2093
Cheryl Corbett
Craig T Jordan
Cyril Benes
Eleni D Lagadinou
Fred K Hagen
Jane L Liesveld
Jeffrey Settleman
Joshua Munger
Kevin P Callahan
P2860
P304
33542-33558
P356
10.1074/JBC.M113.511170
P407
P577
2013-10-02T00:00:00Z